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hormone binding and decreased nuclear translocation. 
Transcriptional activation data, FxxFF-like peptide binding 
and DNA binding correlated well for all variants, except for 
p.Arg609Met, p.Leu723Phe and p.Arg775Leu, which dis-
played a relatively higher peptide binding activity. Variants 
p.Cys177Gly, p.Asp691del, p.Ala766Ser, p.Phe814Cys, and 
p.Ile915Thr had intermediate or wild type values in all assays 
and showed a predominantly nuclear localization in living 
cells. All transcriptionally inactive variants (p.Arg609Met, 
p.Leu701Phe, p.Ser741Tyr, p.Arg775Leu, p.Lys913X) were 
unable to bind to DNA and were associated with complete 
AIS. Three variants (p.Asp691del, p.Arg775Leu, p.Ile915Thr) 
still displayed significant functional activities in in vitro as-
says, although the clinical phenotype was associated with 
complete AIS. The data show that molecular phenotyping 
based on 5 different functional assays matched in most 
(70%) but not all cases.  Copyright © 2013 S. Karger AG, Basel 
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 Abstract 
 Androgen receptor (AR) mutations in androgen insensitivity 
syndrome (AIS) are associated with a variety of clinical phe-
notypes. The aim of the present study was to compare
the molecular properties and potential pathogenic nature
of 8 novel and 3 recurrent AR variants with a broad varie - 
ty of functional assays. Eleven AR variants (p.Cys177Gly, 
p.Arg609Met, p.Asp691del, p.Leu701Phe, p.Leu723Phe,
p.Ser741Tyr, p.Ala766Ser, p.Arg775Leu, p.Phe814Cys,
p.Lys913X, p.Ile915Thr) were analyzed for hormone binding, 
transcriptional activation, cofactor binding, translocation to 
the nucleus, nuclear dynamics, and structural conformation. 
Ligand-binding domain variants with low to intermediate 
transcriptional activation displayed aberrant Kd values for 
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 The androgen receptor (AR) is a ligand-dependent 
transcription factor and belongs to the superfamily of nu-
clear receptors [Laudet et al., 1999]. It is well-known that 
 AR mutations can prevent normal development of both 
internal and external male structures [Quigley et al., 1995; 
Brinkmann, 2001]. End-organ resistance to androgens 
has been designated as androgen insensitivity syndrome 
(AIS) and is distinct from other XY disorders of sex de-
velopment like 17β-hydroxy-steroiddehydrogenase type 
3 deficiency or 5α-reductase type 2 deficiency [Wilson et 
al., 1993; Boehmer et al., 1999; Hughes, 2008]. The  AR 
gene is located on the X chromosome and encodes a 110-
kDa protein of 920 amino acid residues [Brown et al., 
1989; Kuiper et al., 1989; Gottlieb et al., 2012 and www.
androgendb.mcgill.ca]. Structural organization of the 8 
coding exons is essentially identical to those of other ste-
roid hormone receptors [Kuiper et al., 1989]. Also com-
parative structural and functional analysis of nuclear 
 hormone receptors has revealed a common structural 
 organization in 4 different functional domains: an
NH 2 -terminal domain (NTD) that harbors the major 
transcription activation functions and several structural 
subdomains [Jenster et al., 1995], a DNA-binding do-
main (DBD), a hinge region and a ligand-binding domain 
(LBD), of which detailed structural information has been 
published [Matias et al., 2000; Sack et al., 2001; Shaffer et 
al., 2004]. The 3-dimensional structure of the AR-LBD 
has the typical nuclear receptor LBD fold with a ligand-
binding pocket consisting of 18 amino acid residues [Ma-
tias et al., 2000]. Upon interaction with hormone, the AR-
LBD is folded as a sandwich of 11 α-helices and 2 anti-
parallel β-strands, resulting in a hydrophobic groove that 
interacts with LxxLL- and FxxLF-like motifs present in 
AR coregulators and also in the AR-NTD [He et al., 2000; 
Steketee et al., 2002; Dubbink et al., 2006].
 Information of the sequence structure of the  AR gene 
has facilitated the study of molecular defects associated 
with AIS. A large number of mutations in the  AR has been 
identified [Gottlieb et al., 2012; www.androgendb.mcgill.
ca]. The majority of mutations is located in the AR-LBD, 
less frequent are mutations in the AR-DBD, and AR-
NTD mutations are very rare.  AR mutations in X-linked 
AIS are associated with a variety of clinical phenotypes 
[Boehmer et al., 2001]. This provides the opportunity to 
correlate  AR mutations with impairments of specific 
physiological functions. More fundamentally, the natu-
rally occurring  AR mutations are an important source for 
studies of protein structure-function relationships.
 Although several reports have established the patho-
genic nature of  AR variants found in AIS individuals with 
different functional assays [Umar et al., 2005; Wong et al., 
2008; Elfferich et al., 2009; Tadokoro et al., 2009], predic-
tion of phenotypes on the basis of detected mutations can 
be difficult. To optimize molecular diagnosis, an exten-
sive functional analysis of  AR variants is desired. For 
counseling strategies and for future outcome predictions, 
a correct functional diagnosis is very important as well as 
for prognosis on the risks of gonadal malignancy [Cools 
et al., 2011]. A combination of different functional analy-
ses, designed to test  AR variants at different stages in AR 
functioning (e.g. hormone binding, translocation to the 
nucleus, nuclear dynamics, cofactor binding, and tran-
scriptional activation), will provide a more accurate pre-
diction of AR functioning and will help to establish a 
more exact phenotypic characterization.
 The aim of the present study was to determine the mo-
lecular properties and potential pathogenic nature of 8 
novel  AR variants of unknown clinical significance and of 
3 previously reported variants. The outcome of these 
studies will contribute to optimal treatment of the pa-
tients and counseling strategies of relatives. In addition, 
data from this study provides new information on AR 
structure-function relationship.
 Materials and Methods 
 Patients 
 The AIS patient samples were provided by different clinical 
centers in the Netherlands, Belgium and Indonesia, and all se-
quence variants were identified at the Department of Clinical Ge-
netics, Erasmus Medical Center Rotterdam, The Netherlands. In-
formed consent was obtained from patients and/or their parents at 
each center.
 Mutation Analysis 
 Extraction of DNA from peripheral blood cells was performed 
according to standard techniques. The coding exons and exon/in-
tron boundaries of the  AR gene were analyzed by direct sequencing 
on an ABI3730XL automated sequencer (Applied Biosystems, Fos-
ter City, Calif., USA). All mutations were confirmed by a duplicate 
sequencing experiment on the patients’ DNAs.
 The positions of the different mutations (p.Cys177Gly,
p.Arg609Met, p.Asp691del, p.Leu701Phe, p.Leu723Phe,
p.Ser741Tyr, p.Ala766Ser, p.Arg775Leu, p.Phe814Cys, p.Lys913X, 
and p.Ile915Thr) are schematically indicated in  figure 1 A–C. The 
numbering of the amino acid residues is according to the Nation-
al Center for Biotechnology Information (NCBI) reference se-
quence number NM_000044.2, which refers to a gene size of 
187,246 nucleotides and an AR protein of 920 amino acid residues 
with a polyglutamine tract of 23 and a polyglycine tract of 23 [Got-
tlieb et al., 2012; www.androgendb.mcgill.ca]. Nucleotide number-
ing starts at the A of the ATG start codon, according to nomencla-
ture of the Human Genome Variation Society.
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 One of the 11 variants (p.Cys177Gly) was found in an Indone-
sian male partial androgen insensitivity (PAIS) patient and 1 AR-
DBD variant (p.Arg609Met) was found in a complete androgen 
insensitivity (CAIS) patient, whereas the remaining variants were 
localized in the AR-LBD and found in CAIS and PAIS patients. 
Three variants have been reported previously: p.Asp691del in a 
CAIS patient of whom the mother was a carrier; p.Leu723Phe in a 
female PAIS patient and p.Ala766Ser in a male PAIS patient of 
whom the mother was also carrier [Hiort et al., 1996; Chávez et al., 
2001; Tadokoro et al., 2009]. Further information on phenotypes, 
family history and gender identities are summarized in  table 1 .
 Recombinant Plasmids 
 Human wild type  AR (wt  AR ) cDNA expression plasmid 
 pSVAR0 was used to generate constructs encoding mutant  AR s 
using QuickChange site-directed mutagenesis (Stratagene, La Jol-
la, Calif., USA).  Asp 718 and  Bam HI fragments of mutant  AR s were 
exchanged with wild type fragments in pSVAR0 with the exception 
of AR p.Cys177Gly, where  Afl II and  Hin dIII were applied. Most 
GFP-tagged mutant AR expression constructs were generated by 
subcloning of the mutated fragments into pEGFP-AR0 by  Eco RI 
and  Hin dIII digestions [Farla et al., 2004]. The AR p.Cys177Gly 
fragment was subcloned by digestion with  Afl II and  Asp 718. Mu-
tants encoding p.Phe814Cys, p.Lys913X or p.Ile915Thr were gen-
erated using site-directed mutagenesis on pEGFP-AR0. All con-
structs were confirmed by direct sequencing. The Gal4-DBD-AR 
FxxLF, the Gal4-DBD-Gelsolin FxxFF and the Gal4-DBD-SRC 
-3box1 LxxLL peptide expression constructs have been described 
previously [Dubbink et al., 2004; Van de Wijngaart et al., 2006, 
2012].
 Western Blot Analysis 
 For Western blot analysis, Hep3B cells (1.5 × 10 4 cells per plate) 
were seeded in 3 × 6-well plates (Cellstar, Greiner, Frickenhausen, 
Germany) in αMEM (Lonza BioWhittaker) supplemented with 
100 U/ml penicillin, 100 μg/ml streptomycin, 2 m M glutamine and 
5% FCS (HyClone, Thermo Fisher Scientific). Next day the cells 
were washed with PBS, and the medium was substituted by me-
dium containing 5% dextran-coated-charcoal-treated (DCC)-FCS 
(HyClone, Thermo Fisher Scientific) containing 1 n M synthetic 
androgen R1881. Four hours after addition of R1881, the cells were 
transfected with AR expression constructs using FuGENE6 re-
agent (Roche Diagnostics, Basel, Switzerland). Forty-eight hours 
after transfection, 150 μl ice-cold SDS Laemmli sample buffer con-
taining 10 m M dithiotreitol (DTT) was added to each well. The cell 
lysates were transferred to 1.5-ml Eppendorf tubes and boiled for 
2 min. After a short sonication step, 8 μl of the lysate was run on a 
4–12% precast SDS-polyacrylamide gel (Criterion XT Biorad, Her-
cules, Calif., USA). Proteins were separated and blotted to a nitro-
cellulose transfer membrane (Protean, Whatmann, Dassel, Ger-
many). Immunoblotting was performed using polyclonal antibody 
F39.4.1 [Van de Wijngaart et al., 2010]. Proteins were visualized 
via the Super signal Pico chemiluminescent substrate method 
(Thermo, Rockford, Ill., USA).
 Androgen-Binding Assays 
 COS-1 cells (American Type Culture Collection; 1.75 × 10 6 
cells per plate) were seeded into 15-cm 2 plates in DMEM contain-
ing 2 m M glutamine and 10% DCC-FCS supplemented with 100 
U/ml penicillin and 100 μg/ml streptomycin. After 24 h, the me-
dium was exchanged for OptiMEM I medium (Invitrogen). Using 
Lipofectin (Invitrogen), the cells were then transfected with either 
8.5 μg pSVAR0 or AR mutant. Sixteen hours post-transfection, the 
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 Fig. 1.  A Schematic overview of the local-
ization of the different mutations in the
AR protein. Numbering is according to
the NCBI reference sequence number 
NM_000044.2. The international 1-letter 
code is used for amino acid residues. X rep-
resents a premature stop, while del indi-
cates a deletion of an amino acid residue.
 B DNA-binding domain of the AR with the 
location of the p.R609M mutation present 
in the second zinc cluster.  C Positions of the 
mutated residues in the LBD of the AR 
(with exception of p.K913X) are represent-
ed in a 3D model based on X-ray crystal-
lographic data of the AR LBD complexed 
with a reference ligand. 
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cells were transferred to DMEM/FCS. Following further 24 h in-
cubation, the harvested cells were used in a whole cell-binding as-
say with  3 H-labeled mibolerone (Perkin Elmer), as previously de-
scribed [Bevan et al., 1996]. Scatchard analysis was performed us-
ing the Combicept 2000 Steroid Receptor Assay Software (Packard) 
that provided the binding site dissociation constant Kd.
 Transactivation Assays 
 For transcription activation studies, Hep3B cells (5 × 10 4 cells 
per plate) were cultured in αMEM medium supplemented with 5% 
FCS, 100 U/ml penicillin, 2 m M glutamine and 100 μg/ml strepto-
mycin in 24-well plates (Greiner Bio). After 24 h, αMEM supple-
mented with 5% FCS was replaced by αMEM with 5% DCC-FCS 
supplemented with a range of 10 p M –100 n M synthetic androgen 
R1881. Four hours after addition of R1881, the cells were trans-
fected with 50 ng AR expression construct and 100 ng ARE 2 -TA-
TA-Luc reporter plasmid using FuGENE6 reagent. The cells were 
lysed 24 h after DNA transfection, and luciferase activity was mea-
sured in a luminometer (GlowMax Luminometer, Promega).
 Coactivator Binding 
 For coactivator interaction assays, the same procedure of cell 
culture was used as described for transcriptional activation assays 
in presence of 1 n M R1881. A mixture of 50 ng AR expression con-
struct, 50 ng Gal4-DBD-AR FxxLF, Gal4-DBD-Gelsolin FxxFF or 
Gal4-DBD-SRC3box1 LxxLL expression construct, 150 ng (UAS)4-
TATA-Luc reporter plasmid and 1 μl FuGENE was applied per well 
[Van de Wijngaart et al., 2006]. The cells were lysed 24 h after trans-
fection, and luciferase activity was measured in a luminometer.
 Quantitative Live-Cell Imaging of the Subcellular Distribution 
 Two days prior to microscopic analysis, Hep3B cells were 
grown on glass cover slips in 6-well plates in αMEM (Cambrex) 
supplemented with 5% DCC-FCS, 2 m M glutamine, 100 U/ml pen-
icillin, and 100 μg/ml streptomycin. At least 4 h before transfec-
tion, the medium was substituted by medium containing 5% DCC-
FCS. Cells were transfected with 1 μg GFP-AR expression con-
struct in FuGENE transfection medium (Roche). Four hours after 
transfection, the medium was replaced by medium with 5% DCC-
FCS with the indicated concentration of R1881.
 Live-cell imaging was performed using a confocal laser-scan-
ning microscope (LSM510; Carl Zeiss MicroImaging, Inc.) 
equipped with a Plan-Neofluar 40×/1.3 NA oil objective. En-
hanced green fluorescent protein (EGFP) was excited using a 488-
nm argon laser line at moderate laser power, and emission was 
detected using a 505–530-nm bandpass emission filter to obtain 
images for subcellular localization analysis. Fluorescence intensi-
ties were measured in a region of the nucleus and a region just 
outside the nucleus of the cells, and the relative nuclear intensity 
was determined using the equation  I rel-nuc = (( I nuc –  I bg )/( I nuc –  I bg ) 
+ ( I cyt –  I bg )), where  I bg is the background signal.
 Fluorescence Recovery after Photobleaching (FRAP) 
 Sample preparation for strip-FRAP was similar as used for im-
aging of the subcellular distribution. Strip-FRAP analysis was per-
formed with a similar configuration as described by Van Royen et 
al. [2007, 2009]. In short, fluorescence in a narrow strip (1 μm – 
corresponding to 10 pixels) spanning the entire nucleus was 
bleached, and the recovery of fluorescence inside this strip was 
monitored in time with a 100-ms interval using low laser power. 
Fluorescence intensity in the strip was expressed relative to pre-
Table 1. Overview of clinical phenotypes of AIS patients, their mutations and gender identities
Pheno-
typesa
Diagnosis Quigley 
stageb
Social 
sex
Mutation Nucleotide 
change
Location 
mutation
Previously
described
 Family investigations
heterozygous 
carriers
other m embers 
affected
PAIS
P1 penoscrotal hypospadias 3 M p.C177G c.529T>G exon 1 no no information
P2 6 F p.L723F c.2169G>T exon 4 Hiort et al., 1996 mother
P3 M p.A766S c.2296G>T exon 5 Chavez et al., 2001 mother
P4 coronal hypospadias M p.F814C c.2441T>G exon 6 no
CAIS
C1 F p.R609M c.1826G>T exon 3 no
C2 testes present 5 F p.D691del c.2071-2073del-
CAG
exon 4 Tadokoro et al.,
2009
mother
C3 testes present 7 F p.L701F c.2103G>T exon 4 no mother maternal aunt 
(CAIS)
C4 difficult to visualize testes 7 F p.S741Y c.2222C>A exon 5 no mother
C5 inguineal hernia, testes 
present
7 F p.R775L c.2324G>T exon 6 no mother
C6 dysgenetic testes with
Sertoli cell adenomas
7 F p.K913X c.2737A>T exon 8 no no information
C7 gonadectomized 7 F p.I915T c.2744T>C exon 8 no no information
 a P1–P4 = PAIS patients 1 – 4; C1–C7 = CAIS patients 1 – 7. b Quigley et al., 1995.
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bleach intensities  (I prebleach ) and the intensity directly after bleach-
ing  (I 0 ) :  I norm, t = ( I t –  I 0 )/( I prebleach –  I 0 ). AR mutant dynamics was 
directly compared with wt AR and a DNA-binding deficient mu-
tant (p.Ala574Asp) [Farla et al., 2004].
 Structural Analysis of AR Mutants 
 Amino acid residue substitutions were done in a proprietary wt 
AR structure bound to 5α-dihydrotestosterone (DHT). Each mu-
tation has been minimized in Yasara using the Yamber2 force field 
and visually inspected [Krieger et al., 2004]. Sequence and struc-
ture alignments were based on the NuclearRDB [Horn et al., 2001]. 
All pictures were created in PyMOL (PyMOL Molecular graphics 
system, Version 1.2r3pre, Schrödinger, LLC).
 Results 
 Protein Expression Studies and Transcriptional 
Activity 
 Western blot analysis of transiently transfected AR 
mutants shows that the expressed proteins are of the cor-
rect molecular size ( fig. 2 A). Overall negative results in 
functional assays for some of the mutants cannot be ex-
plained by the variation of expression level of the mutant 
proteins.
 AR variants identified in PAIS patients (p.Cys177Gly, 
p.Leu723Phe, p.Ala766Ser, and p.Phe814Cys) induced 
transcriptional activities between 12 and 81% of wild type 
activity at 1 n M R1881 in an ARE 2 -TATA-Luc reporter 
assay ( fig. 2 B). For the p.Leu723Phe mutant, a consider-
able increase in induced activity was observed at 10 n M 
R1881. The p.Phe814Cys mutant, identified in a PAIS pa-
tient, displayed an activity of  ∼ 20% at both 1 and 10 n M 
R1881. These results are in good agreement with the ob-
served PAIS phenotype.
 Considerable activities were also found for 3 variants 
identified in clinically CAIS patients (p.Asp691del, p.Arg -
 775Leu and p.Ile915Thr) at 10 n M R1881; even at 0.1 n M 
R1881 some activity can be measured for p.Asp691del 
and p.Ile915Thr ( fig. 2 C). For 4 other mutants identified 
in CAIS patients (p.Arg609Met, p.Leu701Phe, p.Ser-
741Tyr, and p.Lys913X) no transcriptional activity was 
detectable, even at high hormone concentrations ( fig. 2 C) 
confirming and supporting the clinical findings with re-
spect to the phenotype (CAIS).
 Hormone-Binding Characteristics 
 Scatchard plot analysis with  3 H-mibolerone as syn-
thetic radioactive androgen was performed on a selection 
of mutants that displayed some activity in the transcrip-
tional activation assays (e.g. p.Arg775Leu, p.Phe814Cys, 
p.Ile915Thr) and the previously reported mutants p.Leu-
723Phe and p.Ala766Ser [Hiort et al., 1996; Chávez et al., 
2001] ( table 2 ). A normal Kd value can be expected for 
mutants p.Cys177Gly and p.Arg609Met. The Kd value 
for the p.Asp691del mutant was published previously 
[Tadokoro et al., 2009]. All mutants with some transcrip-
tional activation displayed Kd values that were signifi-
cantly higher than that of the wild type receptor, indicat-
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 Fig. 2.  A Western blot analysis of AR mutants. Wild type AR (wt 
AR) and mutants were expressed in Hep3B cells in the presence of 
1 n M R1881. In addition, a cellular extract of Hep3B cells without 
transfected AR was included as a negative reference (control).
 B ,  C Transcriptional activation assays in Hep3B cells. Dose re-
sponse curves of wt AR, p.C177G, p.L723F, p.A766S and p.F814C 
( B ) and wt AR, p.R609M, p.D691del, p.L701F, p.S741Y, p.R775L, 
p.K913X, and p.I915T ( C ) in the presence of increasing concentra-
tions of R1881 (0–10 n M ). The activity of wt AR at 1 n M R1881 was 
set at 100% and the other data points were calculated relative to 
that. Values represent the means ± SEM of at least 3 experiments, 
each performed in triplicate. 
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ing a decreased affinity for mibolerone, although the Kd 
value did not directly correlate with transcriptional activ-
ity in a quantitative sense.
 Intracellular Distribution and Nuclear Dynamics 
 Intracellular distribution using GFP-tagged AR mu-
tants was investigated in living cells in the presence of dif-
ferent R1881 concentrations ( fig. 3 A, B). In addition, their 
nuclear mobility at 1 n M R1881 was studied using FRAP 
technology and compared to wt AR that shows a transient 
immobilization due to DNA binding (positive control), 
and a DNA-binding deficient AR mutant (p.Ala574Asp; 
negative control) which lacks this transient immobiliza-
tion, as is shown in several previous studies ( fig. 4 A–K) 
[e.g. Farla et al., 2004; Van Royen et al., 2009]. The tran-
scriptionally active mutants p.Cys177Gly, p.Asp691del, 
p.Ala766Ser, p.Phe814Cys, and p.Ile915Thr all displayed 
nuclear localization similar to that of the wt AR ( fig. 3 A, B; 
as typical examples only p.Phe814Cys and p.Ile915Thr are 
shown). Two mutants with minimal transcriptional acti-
vation activities were either mainly nuclear (p.Arg775Leu) 
or distributed equally between cytoplasm and nucleus 
(p.Leu723Phe;  fig. 3 A, B) in the presence of 1 n M R1881. 
Only in the presence of 100 n M R1881, a maximal nuclear 
translocation was observed for these mutants, which could 
explain their minimal transcriptional activation activities 
( fig. 3 A, B; only p.Leu723Phe is shown).
 In comparison with wt AR (showing transient immo-
bilizations) and a non-DNA-binding mutant (Ala574Asp; 
only freely mobile), the mutants p.Asp691del, p.Leu-
723Phe, p.Ala766Ser, p.Phe814Cys, and p.Ile915Thr 
showed an intermediate immobilization in the FRAP ex-
periments, but Asp691del and Leu723Phe were more mo-
bile than the other 3 mutants ( fig. 4 C, E, G, I and K, re-
spectively). p.Cys177Gly displayed wt AR immobiliza-
tion ( fig. 4 A). This is in contrast to p.Arg775Leu ( fig. 4 H) 
that lacked completely nuclear transient immobilization.
 Transcriptionally inactive p.Leu701Phe, p.Ser741Tyr 
and p.Lys913X displayed a predominantly cytoplasmic 
localization, even at a high R1881 concentration (10 n M ), 
whereas the transcriptionally inactive DBD mutant
p.Arg609Met was mainly nuclear (results not shown). 
The homogeneous nuclear distribution of p.Arg609Met, 
unlike the speckled distribution as found for wt AR 
( fig. 3 A), correlated well with the lack of immobilization 
measured by FRAP, similar to the previously published 
non-DNA-binding mutant p.Ala574Asp ( fig. 4 B) [Farla 
et al., 2004; Van Royen et al., 2007]. Similarly, the small 
nuclear fractions of p.Leu701Phe, p.Ser741Tyr and p.Ly-
s913X displayed a rapid redistribution pattern after pho-
tobleaching, indicative of absence of nuclear immobiliza-
tion ( fig. 4 D, F and J, respectively). In these mutants, the 
results reflected the absence of ligand activation, indirect-
ly resulting in the inability to stably bind to DNA, where-
Table 2. Summary of functional studies performed on the different AR mutants
Mutation AR
domain
Patientsa % Transcription 
activationb
Kd
nM ± SDc
C/N distri-
butionb
DNA 
bindingb
% Peptide 
bindingb, d
Published phenotype 
[ref.]
wt AR 100 0.40 ± 0.09 C<<N ++ 100
p.C177G N-term P1 68 n.m. C<<N ++ 52 novel
p.L723F LBD P2 12 1.72 ± 0.35 C=N +/– 27 CAIS [Hiort et al.,1996]
p.A766S LBD P3 81 0.91 ± 0.24 C<<N + 59 PAIS [Chávez et al., 2001]
p.F814C LBD P4 23 1.22 ± 0.29 C<<N + 33 novel
p.R609M LBD C1 0 n.m. C<<N – 90 novel
p.D691del LBD C2 53 1.06e C<<N +/– 60 PAIS [Tadokoro et al., 2009]
p.L701F LBD C3 0 n.m. C>>N – 2 novel
p.S741Y LBD C4 0 n.m. C>>N – 1 novel
p.R775L LBD C5 3 0.93 ± 0.68 C<N – 30 novel
p.K913X LBD C6 0 n.m. C>>N – 1 novel
p.I915T LBD C7 23 1.23 ± 0.49 C<<N + 24 novel
 C/N = Cytoplasmic/nuclear distribution; LBD = ligand-binding domain; n.m. = not measured; N-term = NH2-terminal domain; – = 
no DNA binding; ++ = DNA binding; + = reduced DNA binding; +/– = intermediate DNA binding.
a P1–P4 = PAIS patients 1 – 4; C1–C7 = CAIS patients 1 – 7 (see table 1). b In the presence of 1 nM R1881. c Kd values were calculated 
from the negative inverse of Scatchard plots. Kd values (in nM) are given as the means ± SD of at least 3 independent binding assays 
performed in COS-1 cells with 3H-mibolerone. d FxxFF motif peptide. e Tadokoro et al., 2009.
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as the p.Arg609Met substitution still enabled ligand bind-
ing and nuclear translocation but directly inhibited stable 
DNA binding. These properties were in accordance with 
the lack of transcriptional activation of the 4 mutants.
 Interactions with an AR Cofactor-Derived α-Helical 
FxxFF Peptide Motif 
 A functional peptide one-hybrid interaction assay was 
designed as described previously [Van de Wijngaart et al., 
2006]. Briefly, Hep3B cells were transiently transfected 
with constructs expressing a Gal4-DBD-FxxFF fusion 
protein (interaction motif present in the context of the 
AR coactivator gelsolin) and full-length AR mutants to-
gether with an (UAS)4-TATA-Luc reporter construct 
and incubated either in the absence or presence of 1 n M 
R1881. For all transcriptionally inactive mutants, insig-
nificant peptide interactions were observed with the ex-
ception of the DBD mutant p.Arg609Met, which dis-
played wild type peptide interaction ( fig. 5 B). All novel 
PAIS mutants and the published PAIS mutants p.Asp-
691del and p.Ala766Ser displayed a relatively high pep-
tide interaction ( fig. 5 A, B). These results correlated well 
with the transcriptional activation data. Remarkably, the 
novel CAIS variants p.Arg775Leu and p.Ile915Thr dis-
played significant activities in both transcriptional activa-
tion and peptide interaction ( figs. 2 C,  5 B). Similar effects 
of the mutations on peptide interactions were found us-
ing the FxxLF motif of the AR-NTD and the LxxLL motif 
of SRC3box1 (results not shown).
 Structural Analysis of AR Mutants 
 Structural and functional consequences of the various 
LBD variants can be predicted based on computer model-
ing of the mutant AR LBDs complexed with a reference 
ligand. In the AR-LBD modeling, the Leu723 residue is in 
close proximity to Lys721, which is one side of the charge 
clamp crucial for recognition and binding of cofactor 
proteins ( fig. 1 C). Changing the size of residue 723 to a 
larger residue, like phenylalanine in mutant p.Leu723Phe, 
prevents the optimal arrangement of Lys721 and explains 
the drop in peptide binding and transcriptional activa-
tion.
 Substitution of Phe814 by a cysteine increases the 
space available in the small hydrophobic pocket, allowing 
a deeper burying of the Leu723 side-chain into the pro-
tein and altering the orientation of Lys721 with a con-
comitant negative effect on transcriptional activation 
( fig. 1 C). Ile915 is in close contact with Phe814, forming 
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 Fig. 3.  A High-resolution confocal image 
analysis of Hep3B cells expressing GFP-
tagged wt AR and AR mutants p.L723F, 
p.F814C and p.I915T.  B In the graphs, the 
relative nuclear intensity is plotted at 3 dif-
ferent R1881 concentrations: 0.1, 1 and 100 
n M , and the corresponding confocal imag-
es. In each graph also the wt AR is plotted. 
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 Fig. 4. Strip-FRAP analysis of Hep3B cells 
expressing GFP-tagged AR mutants
p.C177G ( A ), p.R609M ( B ), p.D691del ( C ), 
p.L701F ( D ), p.L723F ( E ), p.S741Y ( F ), 
p.A766S ( G ), p.R775L ( H ), p.F814C ( I ), 
p.K913X ( J ), and p.I915T ( K ). FRAP analy-
sis of the mutants (red curves) was per-
formed in the presence of 1 n M R1881. Re-
distributions of wild type AR (grey curves) 
and a non-DNA-binding mutant (A574D) 
(black curves) were plotted as references. 
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a direct bridge across the width of the LBD ( fig. 1 C). Sub-
stitution of isoleucine by threonine introduces a polar 
group, affecting Phe814 and consequently transcription-
al activation.
 Ser741 is located at the very heart of the AR-LBD. Giv-
en its close proximity to Phe814 and the ligand-binding 
pocket, it is postulated that in such a tightly packed space, 
where small residues are so conserved, a Ser741Tyr sub-
stitution will have a profound effect on structural integ-
rity of the LBD ( fig. 1 C).
 Helix-2 is in the AR-LBD replaced by a long loop of 
moderately ordered residues. Arg775 plays an important 
role in stabilizing this portion of the structure and forms 
H-bonds to Asn692 and Asp696, and perhaps to His690, 
at the bottom of the loop. Substitution of arginine by a 
leucine removes all 3 stabilizing H-bonds, explaining the 
resulting reduction in transcriptional activation.
 Deletion of aspartic acid at position 691, which is lo-
cated in the loop between helix 1 and helix 3, will likely 
alter orientation of either, or both, His690 and Asn692 
with a resulting negative effect on this important stabiliz-
ing region and consequently on transcriptional activa-
tion.
 Replacing Leu701 by a phenylalanine will inevitably 
result in a clash with Arg775 and Asp696, immediately 
destroying domain stabilizing interactions between these 
2 residues, resulting in a total loss of transcriptional acti-
vation of mutant p.Leu701Phe.
 Structurally, it is difficult to hypothesize why moder-
ate loss of transcriptional activation results from the Ala-
766Ser mutation that would appear to be well-tolerated. 
In this mutant, a new H-bond is introduced to Asp768, 
and perhaps this new H-bond interferes with some re-
quired, but until now unidentified, flexibility.
 Discussion 
 In the present study, molecular properties and the po-
tential pathogenic nature of 8 novel and 3 previously 
identified AR variants are presented. Functionality of the 
mutant receptors was assessed with a variety of assays re-
flecting the spectrum of AR properties in the mechanism 
of action of androgens ( table 2 ;  fig. 6 ). Briefly, after ligand 
binding, the receptor is translocated to the nucleus, and 
the hormone-receptor complex binds specifically to bind-
ing sites on the chromatin. DNA binding is accompanied 
and stabilized by cofactors which bind via specific inter-
action motifs to the receptor. The AR-LBD preferentially 
interacts with cofactors that contain FxxLF motifs [Dub-
bink et al., 2004; Van de Wijngaart et al., 2006]. This fi-
nally results in transcriptional activation and/or suppres-
sion of specific androgen responsive genes and ultimate-
ly in development of a male phenotype. Thus, the 
identification and description of a defect in one or mul-
tiple steps could assist in understanding the observed 
clinical phenotypes in AIS patients [Brüggenwirth et al., 
1998; Umar et al., 2005; Wong et al., 2008; Elfferich et al., 
2009; Tadokoro et al., 2009; Orr et al., 2010].
 At least 3 mutants (p.Leu701Phe, p.Ser741Tyr and p.
Lys913X) directly and 2 mutants (p.Asp691del and
p.Arg775Leu) indirectly interfered at the hormone-bind-
ing step in the cascade of androgen action ( fig. 6 ). This is 
reflected by a lack of nuclear translocation and transcrip-
tional activation combined with reduced cofactor peptide 
binding at physiological hormone concentrations (n M 
range). Four mutations (p.Leu723Phe, p.Ala766Ser, p.Phe-
814Cys, and p.Ile915Thr) have a more specific effect on 
cofactor peptide binding. Arg609Met directly interferes 
with stable DNA binding, and for p.Cys177Gly it may be 
speculated that the mutation directly or indirectly affects 
interaction with cofactors that interact with the NTD.
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 Fig. 5.  A ,  B Interaction assay of an FxxFF-motif peptide as mea-
sured in Hep3B cells transfected with either wild type AR or AR 
mutant constructs. The gelsolin FxxFF motif peptide construct 
and the (UAS)4-TATA-Luc reporter plasmid were used in this in-
teraction assay. Interaction was measured in the absence (open 
bars) and presence of 1 n M R1881 (filled bars). The interaction of 
wt AR at 1 n M R1881 was set at 100% and the other data points 
were calculated relative to that. Values represent the means ± SEM 
of at least 3 experiments, each performed in triplicate On top of the 
bars SD is displayed. 
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 The data as summarized in  table 2 can be clustered into 
3 groups of patients based on clinical and biochemical 
phenotypic appearance. Firstly, a group of patients, des-
ignated as CAIS and with a so-called ‘dead receptor’ in 
functional assays: no transcriptional activation, no DNA 
binding and predominantly cytoplasmic localization (pa-
tients C1, C3, C4 and C6). Secondly, a group of pheno-
typically male PAIS patients (patients P1, P3 and P4): the 
mutations found in the PAIS boys displayed moderate 
but significant activities in all assays ( table 2 ). Thirdly, a 
group of patients (patients P2, C2, C5 and C7) that were 
identified as phenotypically associated with CAIS [Hiort 
et al., 1996 and present study], but according to the data 
set of functional assays it can now be concluded that mod-
erate (P2 and C5) to considerable (C2 and C7) functional 
activities can be attributed to these mutant receptors.
 For some AR mutants in the first group (e.g. p.Leu-
701Phe, p.Ser741Tyr, p.Lys913X), no ligand-binding 
data were generated. These mutants displayed a complete 
absence of activity in 4 different assays, even at relatively 
high hormone concentrations. Obviously, adding hor-
mone binding would have been more complete. Howev-
er, in the indicated cases this extra information is of lim-
ited value, because these mutants do not enter the nucle-
us ( table 2 ), and as a consequence, even in the presence of 
non-physiological high hormone concentrations, these 
mutants are completely inactive. Moreover, the structur-
al predictions indicate a highly unstable LBD. DBD mu-
tant p.Arg609Met found in a CAIS patient displayed no 
transcriptional activation and according to the FRAP 
data is not able to stably bind to DNA.
 The second group of AR mutants found in the 3 phe-
notypically male PAIS patients (patients P1, P3 and P4) 
displayed a transient immobilization similar to wild type 
receptor. Therefore, a defective DNA binding seems not 
the cause of the observed partial transcriptional activa-
tion. These AR mutants are able to translocate efficiently 
to the nucleus even at low hormone concentrations. And, 
interestingly, transcriptional activation by F814C did not 
increase with increased ligand concentration (1 n M to 10 
n M R1881), suggesting that a defective ligand binding is 
not the main problem in this mutant.
 The novel mutation in the NTD (p.Cys177Gly) dis-
played partial activities in coactivator binding and tran-
scriptional activation, and full potential for DNA bind-
ing. Pathogenic mutations in the N-terminal domain are 
very rare in AIS [Gottlieb et al., 2012; www.androgendb.
mcgill.ca]. Almost all are nonsense mutations or dele-
tions/insertions. An amino acid substitution like in the 
p.Cys177Gly case is novel and unique.
 A third group of mutants (p.Asp691del, p.Arg775Leu, 
p.Leu723Phe, and p.Ile915Thr) consists of AR variants 
that all displayed an elevated Kd, a distorted LBD struc-
ture and partial activities for transcriptional activation, 
cofactor peptide binding, nuclear translocation, and dy-
namics. The AIS individual with the p.Asp691del muta-
tion was reported earlier with a PAIS clinical phenotype 
[Tadokoro et al., 2009]. This is an interesting phenome-
Ligand
binding
PhenotypeActivity
DNA
bindingTranslocation
Cofactor (peptide) binding/
N/C interaction
R609M
D691del
L701F
S741Y
R775L
K913X
C177G
L723F
A766S
F814C
I915T
(stabilizing)
 Fig. 6. Schematic representation of the cas-
cade of steps in androgen action involving 
the androgen receptor. The sites which are 
being affected by the different AR muta-
tions based on the outcome of the func-
tional studies are indicated. 
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non. Most likely, additional parameters like properties or 
expression of coactivators, which were not studied in the 
present investigation, can affect the phenotypic expres-
sion of a mutant AR. This can particularly play a role in 
those cases with the same AR mutation in different AIS 
individuals where a different clinical phenotype has been 
reported. However, variables like hormone metabolism 
and even not yet identified mechanisms can not be ex-
cluded. Investigation of this aspect will be highly rele-
vant.
 Comparing the data from  table  2 , it is evident that
p.Ile915Thr and p.Phe814Cys are almost identical in all 
tests; yet it remains unclear why the clinical phenotypes 
are so different.
 The individual with a p.Leu723Phe mutation was ini-
tially clinically indexed as CAIS, but at gonadectomy re-
markable Wolffian duct development became evident, 
suggesting important paracrine androgen action, indicat-
ing a PAIS phenotype.
 Intranuclear mobility of all mutants was studied with 
FRAP, a technology that can provide information on the 
DNA-binding potential [Van Royen et al., 2009, 2011]. 
All transcriptional activation inactive mutants (p.Arg-
609Met, p.Leu701Phe, p.Ser741Tyr, p.Arg775Leu, and 
p.Lys913X) displayed lack of immobilization similar
to a non-DNA-binding mutant control p.Ala574Asp 
[Brüggenwirth et al., 1998; Farla et al., 2004; Van Royen 
et al., 2007]. Intermediate values for the redistribution 
were found for p.Leu723Phe and p.Asp691del. These mu-
tants also displayed intermediate or low transcriptional 
activation activities. In that respect, the FRAP data fitted 
well with the results from the other functional assays.
 The detailed structural modeling information was an 
important additional support in predicting the molecular 
phenotype of the mutant receptor. These predictions 
could only be done for mutations in the DBD and LBD, 
because these subdomains have been crystallized [Matias 
et al., 2000; Sack et al., 2001; Shaffer et al., 2004]. None of 
the mutations is in one of the 18 residues forming the li-
gand-binding pocket [Matias et al., 2000] or is part of the 
recently described BF3 (Binding Function 3) surface on 
the LBD of nuclear receptors including the AR, which can 
be considered as an additional docking site for coactiva-
tors and an allosteric modulator of the adjacent AF-2 
pocket [Buzón et al., 2012; Grosdidier et al., 2012].
 With respect to treatment and counseling of AIS indi-
viduals, it is important that in those cases where no gonad-
ectomy has been performed, the partial activity of the mu-
tant receptor might become a matter of concern during 
puberty and thereafter, in particular if these AIS patients 
are raised as girls. Gonadal steroidogenesis may cause a 
variable degree of virilization. Although it is generally rec-
ognized that gonadal tumor risk is slightly higher in PAIS 
than in CAIS, current knowledge does not allow to predict 
the risk for development of a gonadal germ cell tumor from 
the results of in vitro functional assays [Cools et al., 2011].
 In conclusion, the present investigation on novel AR 
mutations in AIS patients reveals that a combination of 
functional assays and structural analyses is a preferred ap-
proach for assessment of the severity of the mutation and 
for prediction of possible ‘rest-activity’ of the mutant re-
ceptor. An extensive functional classification of unknown 
AR sequence variants, as provided in the current study, is 
of highly relevant importance for clinical patient manage-
ment, counseling strategies and future outcome predic-
tions.
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